arXiv

Causal discovery platform maps vascular metabolic pathways

In data from 720,000 people, the self-evolving system evaluated 2,031 causal questions and identified blood pressure as a convergence node for vascular outcomes.

An artery cross-section with a thicker wall on one side sits beside a dark blue-green liver, large fat cells and smaller gray lipid particles.

Our read

AI & data
Studied:
Preprint: study of 720,000 people
In the record:
The 722nd paper on blood pressure with results in people; 4,973 on record in all.

Editor of record: Boris Djordjevic · AgingResearch.News

Follow @agingbrief

In data from over 720,000 human participants across 48 countries, researchers tested an automated discovery platform called DoAtlas-2 to map causal biomedical mechanisms. The platform integrates 771 resources spanning clinical phenotypes, medical imaging, physiological signals, eight molecular layers, and 4.7 million literature-derived records. DoAtlas-2 formulates questions from evidence gaps, prespecifies causal designs, and updates its network based on empirical results. The system systematically evaluated 2,031 research questions. In the Human Phenotype Project, an initial screening of 1,079 candidate pathway questions yielded statistical support for 756 across vascular, early-glycemic, and hepatic-metabolic systems. Specific analyses identified blood pressure as a convergence node connecting adiposity, hepatic, and lipid phenotypes to vascular outcomes, while an adiposity-inflammation-blood-pressure pathway was largely attenuated after joint adjustment for body mass index and smoking.

Why it matters

Clarifying causal networks across metabolic and vascular systems helps researchers pinpoint specific target mechanisms driving age-related vascular pathology. The framework also provides fully interpretable mediation pathways to predict vascular outcomes.

Caveats

The findings are reported in a preprint that has not yet been peer-reviewed, and the causal pathways are derived from observational population data rather than randomized trials.

Comments

Be the first to comment.